NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives
NHS England is seeking suppliers of pan-genotypic Direct Acting Antiviral treatments for Hepatitis C, along with support for hepatitis C elimination initiatives. The contract runs from April 2026 for two years with optional extensions up to 24 months.
- Closed30 January 2026
- Value£160m
- BuyerNHS England
- CategoryHealth & medical
- RegionUK-wide
You'll want to look if you are a pharmaceutical manufacturer or distributor licensed to supply DAA hepatitis C treatments to the NHS
Might not suit a small firm
- the contract itself is a large one
- it needs coverage across the whole UK
Possible incumbent
Roche Products Ltd, Celltrion Healthcare United Kingdom Limited, and Fresenius Kabi Limited won the equivalent tocilizumab framework in October 2025. Inferred from prior awards to this buyer, not confirmed.